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INTRODUCTION
Alzheimer’s disease (AD) also called Alzheimer disease,
Senile Dementia of the Alzheimer Type (SDAT) or simply
Alzheimer’s is the most common form of dementia where
dementia (from Latin de- “apart, away” + mens “mind”) is
the progressive decline in cognitive function due to
damage or disease in the body beyond what might be
expected from normal aging. Generally it is diagnosed in
people over 65 years of age, although the less-prevalent
early-onset Alzheimer’s can occur much earlier. An
estimated 26.6 million people worldwide had Alzheimer’s
in 2006; this number may quadruple by 2050 (Brookmeyer
et al., 2007). This degenerative and terminal disease was
first described by German psychiatrist Alois Alzheimer
in 1906 by observing the patient Auguste D.
Modern research indicates that the disease is associated
with plaques and tangles in the brain (Tiraboschi et al.,
2004).Brain atrophy reveal the damage caused by
Alzheimer’s disease. Certain regions of the brains-
including the hippocampus and cortex – lose functions
and the normally convoluted surface of the brain
ultimately wastes away. Various studies have found that
groups of people exposed to high levels of aluminum do
not have an increased risk. Moreover, aluminum in
cooking utensils does not get into food and the aluminum
that does occur naturally in some foods, such as potatoes,
is not absorbed well by the body. On the whole, scientists
can say only that it is still uncertain and rather unlikely
that exposure to aluminum plays a role in Alzheimer’s
disease. On the other hand, a recent study suggests that
too much zinc might be the problem. In an experiment,
zinc caused soluble beta amyloid from cerebrospinal fluid
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to form clumps similar to the plaques of Alzheimer’s
disease.
The plaques, often known as â amyloid plaques are focal,
spherical, collections of dilated, tortuous, silver staining,
neuritic process (dystrophic neurites) often around a
central amyloid core, which may be surrounded by clear
halo. Plaques can be found in the hippocampus and
amygdale as well as in the neocortex. The amyloid core
which can be stained by Congo red, contains several
abnormal proteins (like as Amyloid Precursor protein,
Apolipoprotein E and Tau Protein). However,
Neurofibrillary tangles are bundles of filaments in the
cytoplasm of the neurons that displace or encircle the
nucleus They are commonly found in cortical neurons,
especially in the entorhinal cortex, as well as in other in
other sites such as in other sites such as pyramidal cells,
as well as in pyramidal cells of the hippocampus, the
amygdala, the basal forebrain and the raphe nuclei.  In
pyramidal neurons, they often have an elongated “flame”
shape; in rounder cells, the basket wave of fibers around
the nucleus take on a rounded contour. They are visible
in silver staining.
CAUSES OF ALZHEIMER’S DISEASE
According to Amyloid hypothesis, following factors are
responsible for Alzheimer’s disease:
A. Role of  amyloid precursor protein in alzheimer’s
disease: Amyloid Precursor Protein (APP) is a 695-770
amino acid long transmembrane protein. The gene for
this protein is situated on chromosome 21.It has cleavage
site for three enzymes which are- â secretase, á secretase
and ã- secretase. Normally âAPP is cut twice, first by â
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secretase to C99-âAPP, then by ã secretase to either 40 â
amyloid protein (normally 90% produced) or 42 â amyloid
protein (normally 10% produced). Mutation in âAPP gene
found and believed to produce a form of the protein with
shifted amino acids which guide â secretase followed by
ã secretase to cut the protein preferentially into 42 â
amyloid protein which can aggregates and form fibrils.
As APP is encoded from chromosome 21, thus peoples
with Down’s syndrome have an increased risk of
developing familial Alzheimer’s disease. (Lott and Head,
2005).
B. Role of apo lipoprotein E in alzheimer’s disease: Apo
lipoprotein E is coded by the gene APOE on chromosome
19 and it comes in three forms -å2, å3, å4. It plays many
important roles in body like as- transports cholesterol in
body, helps in cellular repair and regeneration. Amyloid
proteins are transported into the cell by membrane bound
protein transporters. In AD there appears to be an
interface with transport of 42 âamyloid protein by APOE
(Apolipoprotein å4 form). Toxic â amyloid fragments
builds up outside the cell. Sometimes the å4 form of
Apolipoprotein (APOE) is selectively removed from
extracellular space instead of the âamyloid-leaving the
latter to cause mischief.
C. Role of tau protein in alzheimer’s disease: Tau
proteins interact with tubulin to stabilize microtubules
and promote tubulin assembly into microtubules. Tau
controlls microtubule stability by phosphorylation which
is regulated by a host of kinases. Hyperphosphorylation
of the tau protein (tau inclusions), can result in the self-
assembly of tangles of paired helical filaments and
straight filaments, forming “Neuro fibrillary tangles”
(Hernández and Avila, 2007).
PROTEOMICS OF ALZHEIMER’S DISEASE
Dr. van Leeuwan by discovering a new type of mutation
suggested that due to molecular reading errors,
transcripts (mRNA) may arise in which two nucleotide
are missing. If these transcripts are translated in the +1
reading frame and the proteins do not decompose, they
may accumulate. Indeed this appeared to be the case: in
the characteristics of the disease (among other things
neurofibrillary tangles and neuritic plaques) of all
Alzheimer patients two of these ‘+1 proteins’, i.e.
ubiquitin B+1 and amyloid precursor protein+1 (UBB+1
and APP+1) have been found. Meanwhile the researchers
have demonstrated that UBB+1 inhibit the action of the
proteasome. The proteasome is involved in the enzymatic
decomposition of many (aberrating) proteins. A not well
functioning ubiquitin-proteasome system may be one of
the causes that eventually nerve cells become less active
and even die. UBB+1 is an important chain in the
neurotoxicity of the beta-amyloid protein (present in
plaques) (Leeuwan, 2001).
SYMPTOMS OF ALZHEIMER’S DISEASE
Following are the different stages of Alzheimer’s disease
with symptoms:
Predementa: The most noticeable deficit is memory loss,
which shows up as difficulty in remembering recently
learned facts and inability to acquire new information.
(Arnáiz and Almkvist., 2003)  Subtle problems with the
executive functions of attentiveness, planning, flexibility,
and abstract thinking, or impairments in semantic memory,
can also be symptomatic of the early stages of AD.
Apathy can be observed at this stage.
Early dementia: In this stage difficulties with language,
executive functions, perception (agnosia), or execution
of movements (apraxia) are more prominent than memory
problems (Forstl and Kurz, 1999). Language problems
are mainly characterized by a shrinking vocabulary and
decreased word fluency. While performing fine motor
tasks such as writing, drawing or dressing, certain
movement coordination and planning difficulties (apraxia)
may be present, making sufferers appear clumsy (Benke,
1993).
Moderate dementia: During this phase complex motor
sequences become less coordinated, reducing the ability
to perform most normal daily living activities, memory
problems worsen, and the person may fail to recognize
close relatives. Common neuropsychiatric manifestations
are wandering, sun downing, irritability and labile affect,
leading to crying, outbursts of unpremeditated
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Table 1. Genetics of alzheimer’s disease.
Chromosome Gene Mutations/Alleles Consequences 
21 Amyloid Precursor Protein 1) Single missense    mutations 
2) Double missense mutations 
3) Trisomy 21(gene dosage effect) 
1)Early-onset AD 
2)Increased Aβ production 
14 Presenilin (PS1)  1) Missense mutations 
2) Splice site mutations 
1) Early-onset AD 
2) Increased Aβ production 
1 Presenilin(PS2)  Missense mutations 
 
1) Early-onset FAD 
2) Increased Aβ production 
19 Apolipoprotein E(Apo E)  Allele ε4 1) Increased risk of development of AD 
2) Decreased age at onset of AD 
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aggression, or resistance to care giving.
Adavanced dementia: In this stage, patients will ultimately
not be able to perform even the simplest tasks without
assistance. Muscle mass and mobility deteriorate to the
point where they are bedridden, and they lose the ability
to feed themselves. Finally comes death, usually caused
directly pressure ulcers or pneumonia etc.
DIAGNOSIS OF ALZHEIMER’S DISEASE
Detecing alzheimer’s by eye test: The amyloid beta
proteins which are a hallmark of Alzheimer’s are also found
in the lens and fluid of the eye. These proteins produce
an unusual type of cataract in a different part of the eye.
Scientists can detect these proteins by injecting a light-
sensitive dye, then shining a laser onto the specific part
of the lens where the cataracts tend to form. The
molecules in the dye bind to the protein molecules, if
they are present, and the light will cause the resulting
molecules to glow. This technique is called quasi-elastic
light scattering.
Detecting alzheimer’s by positron emission tomography
scan: In this technique patients are injected with a
radioactive dye called Pittsburgh Compound-B-or PIB.
Once it reaches the brain, PIB attaches to plaque. Then,
a PET scan reveals areas with the most plaque build-up.
The pattern of PIB retention in the brain suggests that
amyloid plaques formed by Alzheimer’s appearing first
in the frontal cortex areas, then progressing to the parietal
and temporal cortex before ravaging the occipital and
sensory-motor cortex. (Kemppainen et al., 2008)
Other techniques like-EEG Test, MRI Scan etc. are also
used for diagnosis of the disease.
TREATMENTS OF ALZHEIMER’S DISEASE
There are some drugs which are now proven to be
effective for the treatment of Alzheimer’s disease. They
are like as Memantine, Hydergine, Exelon, Ginkgo biloba
extracts (Oyama et al., 1996) etc. Beside these, different
natural products such as Turmeric (Fiala et al., 2007) and
hormonal treatments are also useful.
A. Memantine:Memantine is the first representative of a
moderate affinity NMDA receptor antagonist. NMDA
receptor is a type of ionotropic receptor which is present
in brain and plays an important role in mediating plastic
changes in brain .It has following features –
I. It is highly permeable to Ca2+   ions.
II. It has voltage dependant blockage by Mg2+ ions.
III. It shows slow gating kinetics.
Mode of action: Under normal conditions, learning is
based on detection of sufficiently strong signal over
baseline activity i.e. sufficient signal-to-noise ratio.
Signal-to-noise ratio hypothesis assumes that in
Alzheimer’s disease, due to overactive glutamatergic
system, Mg2+ is not effective enough to play its ‘filtering’
function. In turn, synaptic noise rises, impairing detection
of the relevant signal such as in learning. Memantine is
able to serve as a filter blocking ‘synaptic noise’ and
thereby allowing detection of the relevant signal i.e.
synaptic plasticity is restored. (Danysz and Parsons, 2003)
Side effects: The side effects of using Memantine as
drug for Alzheimer’s disease are as follows:
I.Common symptoms: Dizziness, constipation,
hypertension, headache, somnolence etc.
II.Uncommon symptoms: Gait, Vomiting,
thromboembolism, fatigue, hallucinations, confusion.
B. Ergoloid mesylates :Ergoloid mesylates is a mixture of
the methanesulfonate salts of three dihydrogenated ergot
alkaloids (dihydroergocristine, dihydroergocornine, and
alpha- and beta-dihydroergocryptine). It is now present
in market in different brand names like-Hydergine,
Hydergina, Gerimal, Niloric, Redizork, Alkergot, Cicanol,
Redergin etc. The most important among them is
Hydragine.
Mechanism of action of Hydragine:
I. Hydergine increase blood supply to the brain.
II. Hydergine slows the deposit of the age pigment
lipofuscin in the brain.
III. It Increase oxygen delivered to the brain and protects
the brain from insufficient oxygen supply and also
prevents free radical damage to brain cells (Spiegel, 1983).
IV. Hydergine has also been shown to increase the level
of neurotransmitters in the brain,
V. Hydergine enhances the metabolism of brain cells.
There is also evidence that hydergine stimulates the
growth of dendrite nerve fibers which is normally be
expected to decline with aging.
VI. In experiments it has been found that in young adult
rats, the energy required at synaptic regions are provided
by a large number of small, highly efficient mitochondria,
whereas in old rats, energy is produced by a smaller
number of larger, less efficient mitochondria. But, after
treatment with Hydergine, it can be seen that the total
mitochondrial volume of old rats was nearly the same as
the young rats. Furthermore, the mitochondrial size was
altered to a more youthful direction
VII. Hydergine has also shown itself to be a mild
vasodilator (it enhances brain blood flow) and improves
the uptake of the brain energy molecule – glucose.
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Fig. 1. Chemical structure of Memantine.
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Hydergine also reduces the accumulation of age-related
toxin, lipofuscin.
Side effects: Hydergine has proven itself to be non-toxic
and relatively safe although its potential side effects
include mild nausea, gastric disturbances and bradycardia
and stomach upset.
C. Exelon (Rivastigmine tartrate): Exelon (rivastigmine
tartrate) is a cholinesterase inhibitor.  Exelon is specifically
indicated for the treatment of mild to moderate dementia
of the Alzheimer’s type and for the treatment of mild to
moderate dementia associated with Alzheimer’s disease.
Mode of action of exelon: Based on their structure and
mode of enzyme inhibition, ChEIs can be grouped into
three classes: tertiary and quaternary amines, carbamates,
and organophosphates. Acetyl cholinesterase (AChE),
the enzyme that breaks down ACh, is well characterized.
It has two structural binding sites for ACh, an anionic
site and an esteratic site, in two- and three-dimensional
configurations. The ChEIs are classified according to their
duration of enzyme inhibition as short-acting,
intermediate-acting, or long-acting inhibitors. In contrast
to Exelon, Tacrine and donepezil are short-acting ChEI
that bind to AChE by hydrogen bonding and are
hydrolyzed within minutes by the body’s water. Both
rivastigmine and tacrine bind to AChE, however,
rivastigmine fits into the enzyme’s active site in a similar
fashion to ACh, which results in a “flattening” of the
carbamate moiety over the esteratic site, producing the
prolonged inhibition of AChE.
Like tacrine and donepezil, rivastigmine is hydrolyzed,
but unlike these two agents, it leaves the esteratic site
carbamylated and the phenolic derivative is excreted
rapidly from the body. Sequestration of AChE in the
carbamylated form precludes further enzyme hydrolysis
of ACh. On administration of a single dose, the carbamate
moiety can inhibit enzyme activity up to10 hours. Due to
this longer duration of action, rivastigmine is classified
as an intermediate-acting (pseudo-irreversible) agent.
Side effects :Adverse events associated with the use of
Exelon patch may include nausea, vomiting, diarrhea,
depression, headache, anxiety, anorexia, weight loss etc.
D. Ginkgo biloba:Ginkgo biloba is a type of tree that
has existed for over 200 million years. The extract of dried
leaves of this tree has been shown to have protective
effects against mitochondrial damage and oxidative
stress. There are different variants of Ginkgo biloba
extracts available on the market today. Among them are
EGb 761, LI 1379, and Chinese Ginkgo extract ZGE. Ginkgo
biloba is commonly used in the treatment of early-stage
Alzheimer’s disease, vascular dementia, peripheral
claudication, and tinnitus of vascular origin. Multiple
trials investigating the efficacy of ginkgo for treating
cerebrovascular disease and dementia have been
performed, and systematic reviews suggest the herb can
improve the symptoms of dementia (Oyama et al., 1996).
Mechanism of action of Ginkgo biloba: The mechanism
of action of ginkgo is believed to be produced by its
functions as a neuroprotective agent, an antioxidant, a
free-radical scavenger, a membrane stabilizer, and an
inhibitor of platelet-activating factor via the terpene
ginkgolide B. The different components of Ginkgo biloba
like as Flavonoids contributes to its antioxidant property
& Bilobalides helps to protects nerve cells and
regenerates nerve cells. Other pharmacologic effects
include the following: endothelium relaxation mediated
by inhibition of 3’, 5’-cyclic GMP (guanosine
monophosphate) phosphodiesterase, inhibition of age-
related loss of muscarinergic cholinoceptors and
adrenoceptors; and stimulation of choline uptake in the
hippocampus. Ginkgo extract also has been shown to
inhibit beta-amyloid deposition. Some scientist
hypothesized that Ginkgo biloba treatment would have
beneficial effects on cells exposed to the free radical
hydrogen peroxide (Oyama et al., 1996).
E. Turmeric:Turmeric is best known as one of the
ingredients used to make curry, it also gives ballpark
mustard its bright yellow color. The turmeric plant
(Curcuma longa or Curcuma domestica) is a member of
the ginger family. It has aromatic, somewhat fleshy
rhizomes that, when dried, yield a bright yellow powder
commonly used as a spice or coloring agent - sometimes
both, as in certain yellow mustards.
In herbal medicine, turmeric (in the form of an extract of
Curcuma longa) is known for its action as: Anti-
hapatotoxic, Anti-hyperlipidemic, Anti-inflammatory,
Antitumoral, Antimicrobial, Antifertile and mainly for its
antioxidant property.
Role of turmeric preventing alzheimer’s disease:
I.Curcumin is a polyphenolic diketone from turmeric.
Because of its anti-oxidant and anti-inflammatory effects,
it can reduce levels of amyloid and oxidized proteins and
can prevent cognitive deficits. It can also reduce amyloid
aggregation by metal chelation. Metals can induce Aâ
aggregation and toxicity, and are concentrated in AD
brain. Using spectrophotometry, curcumin’s affinity for
copper, zinc, and iron ions has been quantified.
Zn2+showed little binding, but each Cu2+ or Fe2+ ion
appeared to bind at least two curcumin molecules. Since
curcumin more readily binds the redox-active metals iron
and copper than redox-inactive zinc, curcumin might exert
a net protective effect against Aâ toxicity or might
suppress inflammatory damage by preventing metal
induction of NF-êB.
II. Curcumin may interrupt the production of IL-2, a protein
that can play a key role in the destruction of myelin, the
sheath that serves to protect most nerves in the body.
III. Different studies have suggested that curcumin turns
on a gene that code for the production of antioxidant
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proteins. A study showed curcumin’s role in the induction
of the the heme oxygenase pathway, that produces  the
potent antioxidant bilirubin, which protects the brain
against oxidative injury. Such oxidation is thought to be
a major factor in Alzheimer’s disease. (Calabrese et al.,
2003) Another study confirmed that, curcumin strongly
induces expression of hemeoxygenase-1 (HO-1) gene in
astrocytes from the hippocampal region of the brain.
IV. Using blood samples from Alzheimer’s patients, Fiala
et al., 2007 have shown that bisdemethoxycurcumin
boosts macrophage activity to normal levels, helping to
clear amyloid beta. They also observed that
bisdemethoxycurcumin was more effective in promoting
the clearance of amyloid beta in some patients’ blood
than others, hinting at a genetic element. Further study
revealed the genes involved are MGAT III and Toll-like
receptors, which are also responsible for a number of
other key immune functions. Bisdemethoxycurcumin
enhances the transcription of these genes, correcting
the immune defects seen in Alzheimer’s patients.
ROLE OF VITAMINS IN PREVENTING ALZHEIMER’S
DISEASE
Niacin: A study examined whether dietary vitamin B3
(niacin) could prevent cognitive decline and Alzheimer’s
disease, suggests that  higher intake of niacin did appear
to be associated with a slower annual rate of cognitive
decline, leading the researchers to conclude that dietary
niacin may actually protect against Alzheimer’s disease.
Vitamin E: Scientists has demonstrated that in the animal
form of the amyloid beta peptide, the antioxidant vitamin
E slowed the destruction of brain cells as it appears to in
the human form, but the patients may have complain of
nausea, intestinal cramping, fatigue or blurred
vision(Kappus and Diplock,1992).
ROLE OF HORMONES IN PREVENTING
ALZHEIMER’S DISEASE
Estrogen as alzheimer’s preventer: Animal studies have
shown that administration of estrogen to estrogen-
deficient laboratory animals restores the number of neural
synapses, causes beta-amyloid to be more soluble and
has an antioxidant effect. A recent descriptive study
showed a lower relative risk of Alzheimer’s disease and a
later onset of dementia in those who had taken estrogen,
compared with those who had not. The apparent benefit
was increased if the length of treatment was more than
one year (Goodman et al., 1996).
New cancer drug  may help alzhemiers disease : A new
study shows that the experimental drug BRYOSTATIN
that is proved to be useful in cancer prevention stimulates
proteins needed to form long-term memories, an ability
lost in the early stages of Alzheimer’s disease. Researchers
found treating sea slugs (Hermissenda mollusks) with
the drug-BRYOSTATIN, days before a new learning
activity significantly increased their long-term memory
of the skill. Instead of remembering the skill for a few
minutes as usual, they remembered it for weeks.
Drug for renal disorder cures alzheimers’s disease:
The research project showed that the drug sodium
phenyl butyrate, prescribed until now for patients with
alterations in the urea cycle, eases the fusion of proteins
responsible for neuron connections, thus increasing the
learning capacity of the mice involved. As a result, these
discoveries offer new, promising perspectives for the
treatment of Alzheimer’s disease.
Conclusion
Alzheimer’s disease, which is considered as one of the
curse for mankind, is now become curable at last.
Scientists make it possible by identifying the actual cause
of the disease. The defective cutting pattern of Beta
Amyloid Precursor Protein and dysregulation of Tau
protein are mainly responsible for the disease, although
mutations in different genes of chromosome-1, 14, 19, 21
are also the agents for the disease. The disease can be
diagnosed by using different modern techniques like as-
Eye test, PET scan etc. However, the Alzheimer’s disease
can be cured mainly by using different drugs. Among
them, the most common is Memantine which is, by its
action, a NMDA receptor antagonist. Other drugs like,
Exelon which acts as a cholinesterase inhibitor are also
useful. The drug Hydergine also reduce the harmful
effects of the disease by expressing its medicinal
properties like as increasing blood supply, oxygen and
level of neurotransmitters in the brain cells and by its
antioxidant properties. Among natural products, the leaf
extract of Ginkgo biloba, is also acts as an important drug
to prevent the disease by showing its antioxidant and
neuroprotective effects against the plaques. Treatment
with vitamins like vitamin E and Niacin is also proved to
be useful. Hormonal treatment with Estrogen shows
fruitful result. However, the peoples of Oriental countries
are less affected by Alzheimer’s than from peoples of
Western countries. This is due to the fact that, peoples
of Oriental countries take turmeric in their daily food,
which prevents them from all types of Dementia. The
medicinal effect of turmeric is to reduce the level by
increasing macrophage activity in brain, by acting as metal
chellator, by acting as antioxidant and by other important
functions.  Recent research have suggests that, sea drug
Bryostatin, which is very useful to treat cancer, can also
reduce the level of Aâ amyloid plaque formation. Some
drugs like cx516 proved to be useful in mouse model but
are harmful for human body. Other researchers suggest
that, the drug Sodium Phenylbuterate, which is useful in
renal disorder, can help in curing Alzheimer’s disease. It
has also been found that, peoples who use NSAID (Non
Steroidal Anti-inflammatory Drugs) are less affected by
Alzheimer’s disease. However, studies have shown that
people, who take coffee or tea daily, are also less affected
Suman Pratihar et al. /J. Appl. & Nat. Sci. 2 (1): 159-164 (2010)
164
by the disease. A recent study with animal model indicates
that caffeine appears to block several of the disruptive
effects of cholesterol that make the blood-brain barrier
leaky where blood-brain barrier acts as a filter to protect
the brain from potentially harmful chemicals carried in
the bloodstream(Chen et al.,2008).
Recommendations
Recommendations for Alzheimer disease apply to
dementia disorders in general. The recommendations for
the disease are clinical diagnosis, blood tests,
neuroimaging, electroencephalography (EEG),
cerebrospinal fluid (CSF) analysis, genetic testing, tissue
biopsy, disclosure of diagnosis, treatment of Alzheimer’s
disease, and counseling. The specialist physician plays
an important role together with primary care physicians
in the multidisciplinary dementia teams, which have been
established throughout Europe.
•Consume a low-fat diet.
•Eat cold-water fish (like tuna, salmon, and mackerel) rich
in omega-3 fatty acids, at least 2 to 3 times per week.
•Reduce your intake of linoleic acid found in margarine,
butter, and dairy products.
•Increase antioxidants like carotenoids, vitamin E, and
vitamin C by eating plenty of darkly colored fruits and
vegetables.
•Maintain a normal blood pressure.
•Stay mentally and socially active throughout your life.
•Affected persons should take drugs like Memantine,
Ergoloid Mesylate, Rivastigmine Tartrate and  Ginkgo
biloba extracts.
•Take foods which cooked with Turmeric powder and
take green tea or coffee regularly.
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